EAM Investors LLC Has $423,000 Stake in Corium International Inc (CORI)
EAM Investors LLC lowered its stake in Corium International Inc (NASDAQ:CORI) by 41.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 44,003 shares of the biopharmaceutical company’s stock after selling 31,470 shares during the quarter. EAM Investors LLC’s holdings in Corium International were worth $423,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. Candriam Luxembourg S.C.A. lifted its stake in shares of Corium International by 377.8% in the 4th quarter. Candriam Luxembourg S.C.A. now owns 86,000 shares of the biopharmaceutical company’s stock valued at $826,000 after purchasing an additional 68,000 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Corium International by 33.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 88,445 shares of the biopharmaceutical company’s stock valued at $980,000 after purchasing an additional 22,285 shares during the period. TIAA CREF Investment Management LLC acquired a new position in shares of Corium International in the 2nd quarter valued at $411,000. Teachers Advisors LLC acquired a new position in shares of Corium International in the 2nd quarter valued at $272,000. Finally, Opaleye Management Inc. lifted its stake in shares of Corium International by 15.2% in the 4th quarter. Opaleye Management Inc. now owns 1,060,000 shares of the biopharmaceutical company’s stock valued at $10,186,000 after purchasing an additional 140,000 shares during the period. 87.29% of the stock is currently owned by institutional investors.
In other news, major shareholder Life Sciences Maste Perceptive purchased 510,000 shares of the company’s stock in a transaction on Thursday, January 18th. The shares were purchased at an average price of $12.54 per share, with a total value of $6,395,400.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Perceptive Advisors Llc purchased 50,350 shares of the company’s stock in a transaction on Tuesday, January 16th. The stock was purchased at an average cost of $11.83 per share, for a total transaction of $595,640.50. The disclosure for this purchase can be found here. Company insiders own 30.80% of the company’s stock.
Shares of Corium International Inc (CORI) opened at $12.05 on Friday. Corium International Inc has a 12 month low of $3.44 and a 12 month high of $13.93. The company has a debt-to-equity ratio of 5.91, a current ratio of 1.40 and a quick ratio of 1.34.
Corium International (NASDAQ:CORI) last released its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.06. Corium International had a negative return on equity of 403.15% and a negative net margin of 148.07%. The firm had revenue of $9.32 million for the quarter, compared to the consensus estimate of $7.48 million. equities research analysts predict that Corium International Inc will post -1.43 earnings per share for the current year.
WARNING: “EAM Investors LLC Has $423,000 Stake in Corium International Inc (CORI)” was posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.watchlistnews.com/eam-investors-llc-has-423000-stake-in-corium-international-inc-cori/1906580.html.
About Corium International
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
Want to see what other hedge funds are holding CORI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corium International Inc (NASDAQ:CORI).
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.